Sophie Beale

1.2k total citations
42 papers, 911 citations indexed

About

Sophie Beale is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sophie Beale has authored 42 papers receiving a total of 911 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sophie Beale's work include Melanoma and MAPK Pathways (4 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and HER2/EGFR in Cancer Research (4 papers). Sophie Beale is often cited by papers focused on Melanoma and MAPK Pathways (4 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and HER2/EGFR in Cancer Research (4 papers). Sophie Beale collaborates with scholars based in United Kingdom, United States and Portugal. Sophie Beale's co-authors include A Bagust, Angela Boland, Y Dündar, Nigel Fleeman, J Greenhalgh, Rumona Dickson, James Mahon, Kerry Dwan, Juliet Hockenhull and Eleanor Kotas and has published in prestigious journals such as Health Technology Assessment, BMC Cancer and QJM.

In The Last Decade

Sophie Beale

39 papers receiving 867 citations

Peers

Sophie Beale
Elvira D’Andrea United States
Joshua Ray Switzerland
Ágnes Benedict United States
Shahnaz Khan United States
Xiang Yin United States
Érick Moyneur United States
Maxine D. Fisher United States
Lingyi Lu United States
Nancy Reynoso‐Noverón Mexico
Monica R. McClain United States
Elvira D’Andrea United States
Sophie Beale
Citations per year, relative to Sophie Beale Sophie Beale (= 1×) peers Elvira D’Andrea

Countries citing papers authored by Sophie Beale

Since Specialization
Citations

This map shows the geographic impact of Sophie Beale's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sophie Beale with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sophie Beale more than expected).

Fields of papers citing papers by Sophie Beale

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sophie Beale. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sophie Beale. The network helps show where Sophie Beale may publish in the future.

Co-authorship network of co-authors of Sophie Beale

This figure shows the co-authorship network connecting the top 25 collaborators of Sophie Beale. A scholar is included among the top collaborators of Sophie Beale based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sophie Beale. Sophie Beale is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fleeman, Nigel, Rachel Houten, Sarah J Nevitt, et al.. (2024). Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 28(49). 1–190.
2.
3.
Bresnahan, Rebecca, Rachel Houten, J Greenhalgh, et al.. (2023). Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - Open. 7(4). 525–536.
4.
Chaplin, Marty, Rebecca Bresnahan, Nigel Fleeman, et al.. (2023). Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - Open. 7(6). 863–875. 6 indexed citations
5.
Bresnahan, Rebecca, Rui Duarte, James Mahon, et al.. (2023). Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation. Health Technology Assessment. 27(10). 1–115. 4 indexed citations
6.
Fleeman, Nigel, Rachel Houten, A Bagust, et al.. (2020). Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. Health Technology Assessment. 24(2). 1–180. 30 indexed citations
7.
Hounsome, Juliet, Gerlinde Pilkington, James Mahon, et al.. (2020). Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluation. Health Technology Assessment. 24(30). 1–116. 33 indexed citations
8.
Stainthorpe, Angela, Nigel Fleeman, Rachel Houten, et al.. (2020). Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - Open. 4(4). 563–574. 3 indexed citations
9.
Fleeman, Nigel, Rachel Houten, Marty Chaplin, et al.. (2019). A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer. 19(1). 1209–1209. 34 indexed citations
10.
Stainthorpe, Angela, J Greenhalgh, A Bagust, et al.. (2018). Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 36(10). 1153–1163. 11 indexed citations
11.
Lefebvre, Carol, Julie Glanville, Sophie Beale, et al.. (2017). Assessing the performance of methodological search filters to improve the efficiency of evidence information retrieval: five literature reviews and a qualitative study. Health Technology Assessment. 21(69). 1–148. 30 indexed citations
12.
13.
Fleeman, Nigel, A Bagust, Angela Boland, et al.. (2017). Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 35(10). 1035–1046. 6 indexed citations
14.
Owens, Lynn, Ruwanthi Kolamunnage‐Dona, Alan Owens, et al.. (2016). A Randomized Controlled Trial of Extended Brief Intervention for Alcohol-Dependent Patients in an Acute Hospital Setting. Alcohol and Alcoholism. 51(5). 584–592. 2 indexed citations
15.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2014). Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal. PharmacoEconomics. 33(2). 137–148. 14 indexed citations
16.
Greenhalgh, J, A Bagust, Angela Boland, et al.. (2013). Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma. PharmacoEconomics. 31(5). 403–413. 24 indexed citations
17.
Beale, Sophie, et al.. (2012). Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal. European Journal of Public Health. 22(6). 869–873. 20 indexed citations
18.
19.
Beale, Sophie, et al.. (2006). Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UK. PharmacoEconomics. 24(S1). 21–34. 19 indexed citations
20.
Bagust, A, Marc Evans, Sophie Beale, et al.. (2006). A Model of Long-term Metabolic Progression of Type 2 Diabetes Mellitus for Evaluating Treatment Strategies. PharmacoEconomics. 24(S1). 5–19. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elvira D’Andrea Breakdown of academic impact, for papers by Joshua Ray Breakdown of academic impact, for papers by Ágnes Benedict Breakdown of academic impact, for papers by Shahnaz Khan Breakdown of academic impact, for papers by Xiang Yin Breakdown of academic impact, for papers by Érick Moyneur Breakdown of academic impact, for papers by Maxine D. Fisher Breakdown of academic impact, for papers by Lingyi Lu Breakdown of academic impact, for papers by Nancy Reynoso‐Noverón Breakdown of academic impact, for papers by Monica R. McClain
Rankless by CCL
2026